NCT07162012
- Conditions
- DLBCL, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
- Locations
-
- Shanghai General Hospital Shanghai, China
Clinical trial condition
Lymphoma, T-Cell, Peripheral
Explore clinical trials studying Lymphoma, T-Cell, Peripheral. Study availability and eligibility vary by location and protocol.
239 public trials
60 recruiting studies
Lymphoma, T-Cell, Peripheral trial results
Recruiting
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
NCT04234048
- Conditions
- Angioimmunoblastic T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, +23 more
- Locations
-
- Mayo Clinic Arizona Scottsdale, Arizona, United States
- City of Hope Medical Foundation Duarte, California, United States
- University of Southern California Los Angeles, California, United States
- University of Colorado Anschutz Medical Campus Aurora, Colorado, United States
NCT06947967
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
Recruiting
Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT06160843
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
- Locations
-
- National Cancer Centre, Singapore Singapore
Recruiting
Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
NCT07072221
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China
NCT06244368
- Conditions
- Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
- Locations
-
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC Tianjin, Tianjin Municipality, China
NCT03964480
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
- Locations
-
- Stanford University Stanford, California, United States
- IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Italy
- Palermo_La Maddalena Palermo, Italy
- Terni-Santa Maria Terni, Italy
Recruiting
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
NCT06914037
- Conditions
- Cutaneous T-cell Lymphoma (CTCL), Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
- Locations
-
- Tianjin Medical University Cancer Institute & Hospital Tianjin, Tianjin Municipality, China
NCT06855823
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
Recruiting
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
NCT06151106
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
- Locations
-
- The First Affiliated Hosptial of Xiamen University Xiamen, Fujian, China